Skeletal muscle as a metabolic organ: from glucose uptake to longevity
Why muscle mass and, above all, muscle strength rank among the most robust markers of metabolic health and mortality - and what the evidence truly allows us to claim.
The primary site of glucose uptake
About 80% of the glucose taken up after a meal enters skeletal muscle under insulin stimulation.
In the postprandial state, skeletal muscle is the destination of most of the circulating glucose: it is estimated to account for approximately 80% of insulin-mediated glucose uptake, which positions it as the primary effector organ of glycemic control (DeFronzo & Tripathy, 2009). This centrality has a direct pathophysiological consequence: when muscle loses insulin sensitivity, the body loses its greatest glycemic buffer.
Building on that observation, muscle insulin resistance came to be described as the primary and earliest defect in the trajectory leading to type 2 diabetes, preceding beta-cell dysfunction and overt hyperglycemia by years (DeFronzo & Tripathy, 2009). Muscle, therefore, is not merely locomotor tissue: it is a first-line metabolic organ.
Beyond its glycemic role, muscle serves as the body's largest reserve of protein and amino acids, mobilized in situations of stress, prolonged fasting, trauma, and acute illness. Its depletion compromises the immune response, wound healing, and clinical recovery, which is why preserved muscle mass is described as a survival factor in chronic and acute diseases (Wolfe, 2006).
Sarcopenia: the axis shifts from mass to strength
The 2019 European consensus made low strength - not low mass - the primary criterion for sarcopenia.
For a long time, sarcopenia was understood mainly as the loss of muscle mass associated with aging. The revised European consensus (EWGSOP2) repositioned this understanding: low muscle strength became the primary parameter for defining the condition, while low muscle mass confirms the diagnosis and physical performance characterizes its severity (Cruz-Jentoft et al., 2019).
The change reflects a consistent finding in the literature: strength predicts clinical outcomes - falls, frailty, disability, and mortality - more robustly than mass alone. Mass and strength are correlated but not interchangeable dimensions; an individual may preserve muscle volume and still exhibit reduced strength, a situation with greater adverse prognostic value (Cruz-Jentoft et al., 2019).
In clinical practice, this justifies prioritizing simple strength instruments (such as handgrip) in screening, reserving mass measurements - with their methodological limitations - for diagnostic confirmation.
Strength, muscle mass, and mortality
In the PURE study, each 5 kg lower grip strength was associated with about 16% higher all-cause mortality.
The association between muscle strength and survival was documented on a large scale by the PURE study, which followed about 140,000 adults across 17 countries. Each 5 kg reduction in handgrip strength was associated with approximately 16% higher all-cause mortality and 17% higher cardiovascular mortality, and grip strength proved to be a stronger predictor than systolic blood pressure (Leong et al., 2015).
On the mass side, NHANES III data indicated that a higher muscle mass index was independently associated with lower all-cause mortality in older adults (Srikanthan & Karlamangla, 2014). The finding is consistent with the role of muscle as a metabolic and amino acid reserve (Wolfe, 2006).
Two caveats are essential. First: these data are observational, subject to residual confounding and reverse causality - subclinical diseases simultaneously reduce muscle and strength, inflating the association. Concluding that 'gaining muscle prolongs life' overreaches the evidence. Second: handgrip is a marker of vitality and overall health, useful for stratifying risk, and not an isolated therapeutic target. Training grip strength alone does not reproduce the observed benefit.
| Study | Marker | Population | Main finding | Nature |
|---|---|---|---|---|
| Leong et al., 2015 (PURE) | Handgrip strength | ~140,000 adults, 17 countries | -5 kg = ~16% higher all-cause mortality; predictor superior to systolic BP | Prospective cohort / association |
| Srikanthan & Karlamangla, 2014 | Muscle mass index | Older adults (NHANES III) | Higher index = lower all-cause mortality | Cross-sectional-prospective / association |
| Cruz-Jentoft et al., 2019 (EWGSOP2) | Strength (primary criterion) | Diagnostic consensus | Low strength defines sarcopenia; linked to falls, frailty, and higher mortality | Consensus / definition |
Muscle as an endocrine organ: myokines
Contracting muscle secretes myokines that communicate with the liver, adipose tissue, bone, pancreas, and brain.
Contracting muscle does not merely consume substrates: it secretes. Proteins released by active muscle - the myokines, of which IL-6 is the prototypical example - act in an endocrine and paracrine manner, establishing the concept of skeletal muscle as a secretory organ (Pedersen & Febbraio, 2012).
Subsequent reviews expanded this picture into a genuine inter-organ crosstalk: myokines mediate muscle's communication with adipose tissue, liver, bone, pancreas, and brain, offering a plausible mechanism for the systemic effects of exercise on metabolism and health (Severinsen & Pedersen, 2020).
Interpretive caution is warranted. The concept of endocrine muscle is solid; specific claims, however - for example, about irisin and the 'browning' of adipose tissue in humans - remain debated, partly due to specificity limitations of the early assays. The human physiological relevance of individual myokines should be presented as a hypothesis under investigation, not as an established fact.
Strength training: risk reduction and a J-shaped dose-response
The lowest mortality risk clusters around 30 to 60 minutes per week of muscle-strengthening activity.
Beyond the markers, there is evidence about behavior - muscle-strengthening activities. A meta-analysis of cohorts showed that these activities were associated with about 10 to 17% lower risk of all-cause mortality, cardiovascular disease, cancer, and diabetes (Momma et al., 2022).
The point of greatest clinical interest is the shape of the dose-response relationship: a J-shaped curve, with the lowest risk concentrated around 30 to 60 minutes per week and no additional benefit - with possible attenuation - at very high volumes in isolation (Momma et al., 2022). The notion that 'more strength training is always better' finds no support in these data.
These results describe relative risk reduction in populations, with uncertainty, and not an individual guarantee of preventing diabetes, cancer, or cardiovascular disease. Even so, the finding aligns coherently with the physiology discussed: a more functional muscle takes up glucose better, secretes myokines, and sustains the metabolic reserve.
| Weekly volume | Signal in the evidence | Clinical reading |
|---|---|---|
| None | Higher relative risk of mortality | Reference group |
| ~30 to 60 min/week | Lower risk (bottom of the J-shaped curve) | Range of best observed risk-benefit ratio |
| Very high volumes in isolation | No additional benefit; possible attenuation | Do not assume linear gain |
Synthesis: what the evidence allows - and does not allow - us to claim
Functional muscle is a robust marker of health; causal inference, however, demands caution.
Drawing the threads together: skeletal muscle is the primary organ of glucose uptake (DeFronzo & Tripathy, 2009), a central metabolic reserve (Wolfe, 2006), and an endocrine organ via myokines (Pedersen & Febbraio, 2012; Severinsen & Pedersen, 2020). Reduced strength and mass are consistently associated with higher mortality (Leong et al., 2015; Srikanthan & Karlamangla, 2014).
What the evidence firmly supports: functional muscle is a marker of metabolic health and of mortality risk, and muscle strengthening is associated with lower risk in several chronic diseases (Momma et al., 2022). What it does not authorize: promises of years of life gained, a linear dose-response relationship, or direct causal inference from observational data subject to reverse causality.
The prudent clinical reading is to treat muscle, strength, and strengthening activity as legitimate targets of care and monitoring - integrated into the overall assessment of the patient - without converting them into guarantees of outcome. This content has an educational purpose and does not replace individualized evaluation.
Why this matters for your care
This material is part of the educational content line of Dr. Julian Borges' Library and serves as context for those who wish to understand skeletal muscle as a metabolic organ. If you want to situate these concepts in your own case, start with the Functional Self-Assessment and then delve into the indexed articles gathered in the Library. Educational notice: the associations described here - between strength, muscle mass, and mortality - are mostly observational and do not prove causality; this text has an informational purpose, in accordance with CFM guidelines, and does not constitute a prescription, a promise of results, or a substitute for individualized clinical evaluation.
References
- DeFronzo RA, Tripathy D. Skeletal Muscle Insulin Resistance Is the Primary Defect in Type 2 Diabetes. Diabetes Care 2009;32(Suppl 2):S157-S163. 2009. doi:10.2337/dc09-S302
- Wolfe RR. The underappreciated role of muscle in health and disease. The American Journal of Clinical Nutrition 2006;84(3):475-482. 2006. doi:10.1093/ajcn/84.3.475
- Cruz-Jentoft AJ, Bahat G, Bauer J, et al. (EWGSOP2). Sarcopenia: revised European consensus on definition and diagnosis. Age and Ageing 2019;48(1):16-31. 2019. doi:10.1093/ageing/afy169
- Leong DP, Teo KK, Rangarajan S, et al. (PURE). Prognostic value of grip strength: findings from the Prospective Urban Rural Epidemiology (PURE) study. The Lancet 2015;386(9990):266-273. 2015. doi:10.1016/S0140-6736(14)62000-6
- Srikanthan P, Karlamangla AS. Muscle Mass Index As a Predictor of Longevity in Older Adults. The American Journal of Medicine 2014;127(6):547-553. 2014. doi:10.1016/j.amjmed.2014.02.007
- Pedersen BK, Febbraio MA. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nature Reviews Endocrinology 2012;8(8):457-465. 2012. doi:10.1038/nrendo.2012.49
- Severinsen MCK, Pedersen BK. Muscle-Organ Crosstalk: The Emerging Roles of Myokines. Endocrine Reviews 2020;41(4):594-609. 2020. doi:10.1210/endrev/bnaa016
- Momma H, Kawakami R, Honda T, Sawada SS. Muscle-strengthening activities are associated with lower risk and mortality in major non-communicable diseases: a systematic review and meta-analysis of cohort studies. British Journal of Sports Medicine 2022;56(13):755-763. 2022. doi:10.1136/bjsports-2021-105061
Educational and scientific content. It does not constitute diagnosis, prescription or individual clinical guidance, and does not replace a medical consultation. Management decisions must be individualized by a physician.